Pruritus - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 117 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 12, 4, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pruritus - Overview
Pruritus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pruritus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pruritus - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Alveonix AG
Amorepacific Corp
Asana BioSciences LLC
Cara Therapeutics Inc
Chugai Pharmaceutical Co Ltd
ELORAC Inc
GlaxoSmithKline Plc
Hydra Biosciences Inc
J Uriach Y Compania SA
NeuroCycle Therapeutics GmbH
Nippon Shinyaku Co Ltd
Patagonia Pharmaceuticals LLC
Patara Pharma Inc
Phosphagenics Ltd
RDD Pharma Ltd
Sanwa Kagaku Kenkyusho Co Ltd
Shionogi & Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Teikoku Pharma USA Inc
Tioga Pharmaceuticals Inc
Toray Industries Inc
Trevi Therapeutics Inc
Vanda Pharmaceuticals Inc
Pruritus - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ax-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ax-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
difelikefalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalfurafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCT-10001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCT-10002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCT-10004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PATN-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-1609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rupatadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serlopitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize KOR1 for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CB2 for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPV3 for Pruritus, Psoriasis and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tradipitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Featured News & Press Releases
Jan 06, 2017: Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury
Jan 05, 2017: Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus
Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings
Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting
Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference
Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain
Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis
May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845
Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids
Mar 19, 2015: Creabilis' CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board
Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis
Mar 03, 2015: Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 �g and Notice Regarding Promotion Tie-up
Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration
Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Pruritus, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pruritus - Pipeline by Albireo Pharma Inc, H1 2017
Pruritus - Pipeline by Allergan Plc, H1 2017
Pruritus - Pipeline by Alveonix AG, H1 2017
Pruritus - Pipeline by Amorepacific Corp, H1 2017
Pruritus - Pipeline by Asana BioSciences LLC, H1 2017
Pruritus - Pipeline by Cara Therapeutics Inc, H1 2017
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Pruritus - Pipeline by ELORAC Inc, H1 2017
Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2017
Pruritus - Pipeline by Hydra Biosciences Inc, H1 2017
Pruritus - Pipeline by J Uriach Y Compania SA, H1 2017
Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H1 2017
Pruritus - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1 2017
Pruritus - Pipeline by Patara Pharma Inc, H1 2017
Pruritus - Pipeline by Phosphagenics Ltd, H1 2017
Pruritus - Pipeline by RDD Pharma Ltd, H1 2017
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017
Pruritus - Pipeline by Shionogi & Co Ltd, H1 2017
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Pruritus - Pipeline by Teikoku Pharma USA Inc, H1 2017
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H1 2017
Pruritus - Pipeline by Toray Industries Inc, H1 2017
Pruritus - Pipeline by Trevi Therapeutics Inc, H1 2017
Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H1 2017
Pruritus - Dormant Projects, H1 2017
Pruritus - Discontinued Products, H1 2017